CONMED

CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States, Americas excluding the United States, Europe, Middle East, and Africa, and Asia Pacific. Its products are used by surgeons and physicians in a variety of medical specialties, including orthopedic surgery, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CONMED faces Q4 challenges, eyes growth through margin improvement

CONMED faced challenges in Q4 due to software implementation issues, resulting in revenue delays and lost opportunities.
Despite this, the company aims for revenue growth and margin improvement, with positive signs in sales recovery and operational stability.
2023 financial guidance shows optimism for growth, with a focus on cost reduction, salesforce retention, and new acquisitions.
Efforts to enhance gross margins and normalize operations present opportunities for profitability and market expansion in the coming years.

CONMED reports strong Q1 performance, focuses on innovation and advocacy

CONMED's Q1 2023 showcased robust sales growth and strategic acquisitions, despite challenges.
The company's focus on innovation, customer recovery, and advocacy positions it well for future success.
Resolving warehouse issues and adapting to potential legislation are key priorities for sustained growth.
Maintaining strong performance amidst challenges highlights CONMED's resilience and market positioning.

CONMED reports robust Q2 growth, eyes market expansion opportunities

CONMED's Q2 performance reflects strong sales growth and improved profitability, particularly in international markets.
The company faces challenges in convincing health systems to adopt pricier procedures and transitioning its sales focus.
Opportunities lie in demonstrating product value, expanding market share, and investing in growth areas like In2Bones and BioBrace.
Overall, CONMED's strategic focus on innovation and market expansion positions it for continued success in the medical device industry.

CONMED reports solid Q3 earnings, anticipates growth despite challenges

CONMED's Q3 performance showed growth in sales and adjusted net income, despite facing supply constraints. The company remains optimistic about future organic growth and expects improvements in margins and FX impact for 2024. Financial stability and strong product performance position CONMED well for future growth.

CONMED reports record revenue in Q4, eyes growth amid challenges

CONMED delivered strong financial performance in Q4 2023, with robust revenue growth and margin improvement, setting optimistic revenue guidance for 2024.
Strategic acquisitions and focus on profitability highlight CONMED's strengths, while challenges like supply disruptions and market dynamics require careful navigation.
Opportunities lie in M&A prospects, BioBrace's growth potential, and differentiation strategies, positioning CONMED for continued success in the medical devices market.

CONMED posts robust Q1 results, adjusts guidance amidst currency impact

CONMED's Q1 results reflect strong financial performance, operational improvements, and strategic leadership changes, setting a positive tone for future growth.
While facing challenges such as currency impacts and guidance adjustments, the company's resilience and commitment to growth remain evident in its revised projections.
With a focus on operational efficiency, market expansion, and maintaining growth momentum, CONMED is poised to navigate challenges and leverage opportunities for sustained success.

CONMED reports Q2 growth, faces Orthopedic supply challenges

CONMED's Q2 performance showed overall growth, with notable strength in the general surgery segment.
Challenges in the Orthopedic side impacted sales and guidance for the year.
The company's focus on cost management and margin improvement is evident in the financial results.
Balancing supply chain issues while capitalizing on general surgery opportunities will be key moving forward.

CONMED reports strong Q3 earnings amidst leadership transition and challenges

CONMED's Q3 performance reflects a resilient financial standing and strategic leadership transition, setting the stage for continued growth.
While challenges like hurricane impacts and supply chain disruptions persist, CONMED's strengths in key segments provide a foundation for future success.
The company's focus on operational efficiency, growth opportunities, and leadership continuity positions CONMED well for sustainable profitability and market expansion.
Navigating challenges and capitalizing on growth opportunities will be crucial for CONMED to drive innovation and maintain its competitive edge in the medical device industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. Its products include AirSeal and insufflation, allograft cartilage and tissue, arthroplasty, biliary and endoscopic ultrasound, biomedical sensors and electrodes, biopsy and polypectomy, dilators and accessories, electrosurgical units, fixation devices, hemostasis, implants and suture anchors, infection prevention, patient positioning, and related products. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Conmed (CNMD) is a Strong Growth Stock

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will participate in fireside chats at the following two investor conferences in November: Conference: Stifel Healthcare Conference Location: New York, NY Date: Tuesday, November 19, 2024 Presentation: 8:35 a.m. ET Speakers: Curt R. Hartman, President and Chief Executive Officer, and Nate Miersma, Vice President and General Manager, U.S. Orthopedics Conference: Jefferies London Healthcare Conference Location: L.

CONMED Corporation to Participate in Fireside Chats at Two Investor Conferences on November 19-20

CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.

CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View

CONMED Corporation (NYSE:CNMD ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Curt Hartman – Chairman, President and Chief Executive Officer Pat Beyer – Chief Operating Officer Todd Garner – Executive Vice President and Chief Financial Officer Conference Call Participants Kristen Stewart – C.L. King Lily Delaney – JPMorgan Dino Weinstock – Wells Fargo Operator Good day and thank you for standing by.

CONMED Corporation (CNMD) Q3 2024 Earnings Call Transcript

The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Conmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to Say

Conmed (CNMD) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.90 per share a year ago.

Conmed (CNMD) Surpasses Q3 Earnings Estimates

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Sales of $316.7 million increased 4.0% year-over-year as reported and 4.3% in constant currency. Diluted net earnings per share (GAAP) were $1.57 compared to diluted net earnings per share (GAAP) of $0.50 in the third quarter of 2023. Adjusted diluted net earnings per share(1) were $1.05, an increase of 16.7% compared to th.

CONMED Corporation Announces Third Quarter 2024 Financial Results

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman will retire as President and Chief Executive Officer (CEO) of the Company, effective January 1, 2025. Patrick Beyer, current Chief Operating Officer (COO) of CONMED, will succeed Mr. Hartman as President and CEO and will also be appointed as a member of the Company's board, effective the same date. As part of the transition, Lead Independent Director Martha Goldberg Aronson will assume the positio.

CONMED Corporation Announces Leadership Succession

Conmed (CNMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conmed (CNMD) Earnings Expected to Grow: Should You Buy?

Conmed (CNMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Conmed (CNMD) Beat Estimates Again in Its Next Earnings Report?

CNMD is poised for growth with strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.

Here's Why You Should Retain CONMED Stock in Your Portfolio

LARGO, Fla.--(BUSINESS WIRE)--As a follow up to the Current Report on Form 8-K issued by the Company on September 30, 2024, CONMED Corporation (NYSE: CNMD) announced preliminary financial information for the third quarter of 2024. The Company expects revenue in the range of $315 million to $318 million and adjusted diluted net earnings per share growth in excess of its previously provided guidance of 9% to 11%. CONMED will report full financial results for the third quarter of 2024 after the ma.

CONMED Corporation Announces Preliminary Third Quarter Financial Information

Amerant Bancorp

Beazer Homes USA

AMTB, BZH and CNMD have been added to the Zacks Rank #24 (Strong Sell) List on September 26, 2024.

New Strong Sell Stocks for September 26th

BAMXF, BZH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on September 17 2024.

New Strong Sell Stocks for September 17th

Dublin, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The "Carpal Tunnel Release Systems - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Carpal Tunnel Release Systems was estimated at US$604.4 Million in 2023, and is projected to reach US$809.7 Million by 2030, growing at a CAGR of 4.3% from 2023 to 2030. The growth in the carpal tunnel release systems market is driven by several factors, including technological advancements, an increase in the prevalence of conditions requiring such interventions, and heightened patient preference for minimally invasive procedures. The continuous development of new technologies such as enhanced endoscopic equipment and improved surgical techniques contributes significantly to the efficacy and safety of carpal tunnel surgeries, appealing to both surgeons and patients.

Carpal Tunnel Release Systems Market Forecast Report 2024-2030, Featuring Profiles of Arthrex, Conmed, Innomed, MicroAire Surgical Instruments, Resurgens Orthopaedics, S2S Surgical and Trice Medical

Barnes Group

B, CNMD and CHEOY have been added to the Zacks Rank #5 (Strong Sell) List on September 11, 2024.

New Strong Sell Stocks for September 11th

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the CL King 22nd Annual Best Ideas Conference at 10:15 a.m. ET on Monday, September 16, 2024. A live video webcast of the fireside chat will be accessible through the “Investors” section of the Company's website at www.

CONMED Corporation to Participate in a Virtual Fireside Chat at the CL King Best Ideas Conference

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

Why Is Conmed (CNMD) Up 13.2% Since Last Earnings Report?

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Wells Fargo Healthcare Conference at 8:00 a.m. ET on Wednesday, September 4, 2024. A live webcast of the fireside chat will be accessible through the “Investors” section of the Company's website at www.conmed.com and will.

CONMED Corporation to Participate in a Fireside Chat at the Wells Fargo Healthcare Conference

Array Technologies

Black Stone Minerals LP

ARRY, BSM and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2024.

New Strong Sell Stocks for August 19th

Arcos Dorados Hlds

CVS Health

ARCO, CNMD and CVS have been added to the Zacks Rank #5 (Strong Sell) List on August 15, 2024.

New Strong Sell Stocks for August 15th

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 8, 2024, payable on October 4, 2024, to all shareholders of record as of September 16, 2024. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, inc.

CONMED Corporation Announces Quarterly Cash Dividend

America Movil SAB de CV

AMX, CNH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2024.

New Strong Sell Stocks for August 5th

CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.

CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut

CONMED Corporation (NYSE:CNMD ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Curt Hartman – Chair of the Board, President and Chief Executive Officer Todd Garner – Executive Vice President and Chief Financial Officer Pat Beyer – Chief Operating Officer Conference Call Participants Rick Wise – Stifel Robbie Marcus – JPMorgan Dino Weinstock – Wells Fargo Travis Steed – BofA Mike Matson – Needham Kristen Stewart – CL King Operator Good day, and thank you for standing by. Welcome to CONMED's Second Quarter Fiscal 2024 Earnings Conference Call.

News for CONMED Stock (CNMD)